Volume 13 Issue 6
Nov.  2022
Turn off MathJax
Article Contents
Chinese Urological Doctor Association Adrenal Hypertension Surgery Collaborative Organization Adrenal Group, Chinese Society of Endocrinology PET group, Chinese Society of Nuclear Medicine. Consensus on Clinical Application of the CXCR4-targeted Imaging in the Diagnosis of Primary Aldosteronism(2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 986-991. doi: 10.12290/xhyxzz.2022-0584
Citation: Chinese Urological Doctor Association Adrenal Hypertension Surgery Collaborative Organization Adrenal Group, Chinese Society of Endocrinology PET group, Chinese Society of Nuclear Medicine. Consensus on Clinical Application of the CXCR4-targeted Imaging in the Diagnosis of Primary Aldosteronism(2022)[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 986-991. doi: 10.12290/xhyxzz.2022-0584

Consensus on Clinical Application of the CXCR4-targeted Imaging in the Diagnosis of Primary Aldosteronism(2022)

doi: 10.12290/xhyxzz.2022-0584
Funds:

National High Level Hospital Clinical Research Funding 2022-PUMCH-C-028

National High Level Hospital Clinical Research Funding 2022-PUMCH-B-010

CAMS Innovation Fund for Medical Sciences 2022-I2M-JB-001

  • Received Date: 2022-10-09
  • Accepted Date: 2022-10-25
  • Available Online: 2022-11-07
  • Publish Date: 2022-11-30
  • Subtype classification of primary aldosteronism is important but challenging. Increasing evidence has shown that 68Ga-Pentixafor PET/CT imaging which targets CXCR4 is beneficial to the subtype classification of primary aldosteronism. Based on all the available evidence, and after in-depth discussion of a group of multi-disciplinary experts, a consensus has been established, which covers imaging technology, interpretation of results of CXCR4 imaging, and the guidance to the choice of the treatment and prognosisevaluation. The consensus is helpful for standardizing 68Ga-Pentixafor PET/CT imaging and promoting a better diagnosis procedure in primary aldosteronism.
  • loading
  • [1] Funder JW, Carey RM, Mantero F, et al. The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline[J]. J Clin Endocrinol Metab, 2016, 101: 1889-1916. doi:  10.1210/jc.2015-4061
    [2] Mulatero P, Monticone S, Deinum J, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension[J]. J Hypertens, 2020, 38: 1919-1928. doi:  10.1097/HJH.0000000000002510
    [3] Wang H, Wang F, Zhang Y, et al. Surgical Outcomes of Aldosterone-Producing Adenoma on the Basis of the Histopathological Findings[J]. Front Endocrinol (Lausanne), 2021, 12: 663096. doi:  10.3389/fendo.2021.663096
    [4] Mulatero P, Sechi LA, Williams T A, et al. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension[J]. J Hypertens, 2020, 38: 1929-1936. doi:  10.1097/HJH.0000000000002520
    [5] Walenkamp A, Lapa C, Herrmann K, et al. CXCR4 Ligands: The Next Big Hit?[J]. J Nucl Med, 2017, 58: 77S-82S. doi:  10.2967/jnumed.116.186874
    [6] Heinze B, Fuss CT, Mulatero P, et al. Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma[J]. Hypertension, 2018, 71: 317-325. doi:  10.1161/HYPERTENSIONAHA.117.09975
    [7] Ding J, Zhang Y, Wen J, et al. Imaging CXCR4 expression in patients with suspected primary hyperaldosteronism[J]. Eur J Nucl Med Mol Imaging, 2020, 47: 2656-2665. doi:  10.1007/s00259-020-04722-0
    [8] Ding J, Tong A, Zhang Y, et al. Functional Characterization of Adrenocortical Masses in Nononcologic Patients Using (68)Ga-Pentixafor[J]. J Nucl Med, 2022, 63: 368-375. doi:  10.2967/jnumed.121.261964
    [9] Ding J, Tong A, Zhang Y, et al. Intense 68Ga-Pentixafor Activity in Aldosterone-Producing Adrenal Adenomas[J]. Clin Nucl Med, 2020, 45: 336-339. doi:  10.1097/RLU.0000000000002946
    [10] Gao Y, Ding J, Cui Y, et al. Functional nodules in primary aldosteronism: identification of CXCR4 expression with (68)Ga-Pentixafor PET/CT[J]. Eur Radiol, 2022. doi:  10.1007/s00330-022-09058-x.
    [11] Song Y, Yang J, Shen H, et al. Development and validation of model for sparing adrenal venous sampling in diagnosing unilateral primary aldosteronism[J]. J Hypertens, 2022, 40: 1692-1701. doi:  10.1097/HJH.0000000000003197
    [12] Fu B, Zhang X, Wang GX, et al. Long-term results of a prospective, randomized trial comparing retroperitoneoscopic partial versus total adrenalectomy for aldosterone producing adenoma[J]. J Urol, 2011, 185: 1578-1582. doi:  10.1016/j.juro.2010.12.051
    [13] 中华医学会内分泌学分会. 原发性醛固酮增多症诊断治疗的专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36: 727-736. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ202111003.htm

    Chinese Society of Endocrinology. Expert consensus on the diagnosis and treatment of primary aldosteronism (2020)[J]. Zhonghua Neifenmi Daixie Zazhi, 2020, 36: 727-736. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGGZ202111003.htm
    [14] Steichen O, Zinzindohoué F, Plouin PF, et al. Outcomes of adrenalectomy in patients with unilateral primary aldosteronism: a review[J]. Horm Metab Res, 2012, 44: 221-227. doi:  10.1055/s-0031-1299681
    [15] Williams TA, Lenders JWM, Mulatero P, et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort[J]. Lancet Diabetes Endocrinol, 2017, 5: 689-699. doi:  10.1016/S2213-8587(17)30135-3
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (878) PDF downloads(398) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return